Raymond James Financial Services Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Raymond James Financial Services Advisors’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,538	Closed	-$13.4K	–	3454
2023 Q3	$13.4K	Sell	12,538 -797	-6%	-$1.65K	﹤0.01%	3217
2023 Q2	$34.5K	Sell	13,335 -22,072	-62%	-$78.7K	﹤0.01%	3152
2023 Q1	$144K	Sell	35,407 -18,020	-34%	-$83.3K	﹤0.01%	2994
2022 Q4	$268K	Sell	53,427 -31,459	-37%	-$197K	﹤0.01%	2667
2022 Q3	$1.11M	Buy	84,886 +22,199	+35%	+$336K	﹤0.01%	1747
2022 Q2	$804K	Buy	62,687 +33,596	+115%	+$465K	﹤0.01%	1969
2022 Q1	$444K	Buy	+29,091	New	+$454K	﹤0.01%	2455
2020 Q4	–	Sell	-14,057	Closed	-$224K	–	3108
2020 Q3	$224K	Sell	14,057 -2,197	-14%	-$40.1K	﹤0.01%	2468
2020 Q2	$321K	Buy	+16,254	New	+$311K	﹤0.01%	2190

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial Services Advisors's NGM Position: Q4 2023 in Review

Raymond James Financial Services Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2023, closing a stake of 12,538 shares — an estimated $13.4K sold.

Raymond James Financial Services Advisors first reported a position in NGM in Q2 2020 and held it in 9 quarters. The position peaked at $1.11M in Q3 2022. 83 funds tracked by Wall St. Rank hold NGM as of Q4 2023.

Raymond James Financial Services Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Raymond James Financial Services Advisors sold 12,538 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $13.4K.
Raymond James Financial Services Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 9 quarters.
Raymond James Financial Services Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.11M in Q3 2022.
83 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.